Pre-Made Efruxifermin Biosimilar, Fusion Protein targeting FGFR1 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting BFGFR/CD331/CEK/ECCL/FGFBR/FGFR-1/FLG/FLT-2/FLT2/HBGFR/HH2/HRTFDS/KAL2/N-SAM/OGD/bFGF-R-1 for drug discovery and mechanism of action (MOA) research

Pre-Made Efruxifermin Biosimilar, Fusion Protein targeting FGFR1 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting BFGFR/CD331/CEK/ECCL/FGFBR/FGFR-1/FLG/FLT-2/FLT2/HBGFR/HH2/HRTFDS/KAL2/N-SAM/OGD/bFGF-R-1 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Efruxifermin is a differentiated Fc-FGF21 fusion protein designed to mimic the biological activity of fibroblast growth factor 21 (FGF21), which regulates multiple metabolic pathways and cellular processes. Efruxifermin is a fusion protein of human IgG1 Fc domain linked to a modified human FGF21 (Fc-FGF21) with balanced in vitro agonist potency at FGFR1c, FGFR2c and FGFR3c. FGF21 is a key regulator of whole-body and individual organ metabolism. It activates a cell membrane co-receptor complex of β-klotho and one of its cognate FGF receptors (FGFRs), FGFR1c, FGFR2c or FGFR3c. FGF21 and its analogs improve metabolic status in preclinical models of obesity, diabetes and NASH. Efruxifermin is longer acting than most FGF21 analogs, with a 3–3.5-d half-life.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-826-1mg	1mg	3090
GMP-Bios-INN-826-10mg	10mg	Inquiry
GMP-Bios-INN-826-100mg	100mg	Inquiry
GMP-Bios-INN-826-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Efruxifermin Biosimilar, Fusion Protein targeting FGFR1 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting BFGFR/CD331/CEK/ECCL/FGFBR/FGFR-1/FLG/FLT-2/FLT2/HBGFR/HH2/HRTFDS/KAL2/N-SAM/OGD/bFGF-R-1
INN Name	Efruxifermin
Target	FGFR1
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - IGHG1 Fc (Fragment constant) - [FGF21 (fibroblast growth factor 21)]2
VD LC	Fusion - IGHG1 Fc (Fragment constant) - [FGF21 (fibroblast growth factor 21)]2
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Amgen (Thousand Oaks CA USA) / Akero Therapeutics (South San Francisco CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0